#EHA24 in other bispecific news
phase Ib co-stim englumafusp alfa (CD19/4-1BBL) + glofit in r/r aggressive lymphoma
n=134, standard glofit; englumafusp (0.35-75mg)
CRS 55% G1 48%
CR rate 57% (!) ORR 67%
need expansion to see additive effect #lymSM
library.ehaweb.org/eha/2024/eha20…

I calculated the total cost for giving #glofitamab . ~$358k for only the drugs, not including hospitalization for the first dose, CRS management, and other side effect management costs.

Had good news from PeterMac yesterday regarding scan results. The lymphoma has responded to the glofitamab and is in stasis. It’s expected to return one day but now I have a drug that can at least control it. Stay healthy friends, you don’t want this stuff. ❤️

Great to see our consensus guidelines on CD20x3 #bispecific safety management in a nice PDF @bloodjournal bit.ly/3SvFfhl. Hopefully a useful resource for the roll out of these potent drugs #lymsm #glofitamab #Epcoritamab #mosunetuzumab

Summary of 10 new indications/approvals in Heme Malignancies (excluding CART) by FDA Oncology in 2023:

1. #Zanubrutinib
2. #Pirtobrutinib
3. #Polatuzumab
4. #Epcortimab
5. #Glofitamab
6. #Quizartinib
7. #Talquetamab
8. #Elranatamab
9. #Ivosidenib

#HemeTwitter #MedTwitter

A first for RCHT Cancer Services and potentially the UK! We successfully delivered a new bispecific antibody for refractory lymphoma, Glofitamab to the first patient in Cornwall.
Well done to both Lowen Ward and the Haematology team ⭐️ 🩸 👩‍⚕️
Juliet Rickard Sarah Caskey RCHT

At #Blood2023 Adrian Minson presents interim analysis of COALITION RCT in high risk DLBCL of glofitamab + R-CHOP vs. glofitamab-pola-RCHP
Allowed enrolment after C1 to facilitate recruitment of high risk patients- 72% entered trial prior to C2
100% ORR & good early survival data

欧州委員会、Rocheのリンパ腫治療薬Columvi（glofitamab）の使用を承認👏

Columviは『再発または難治性の拡散性大細胞B細胞リンパ腫（DLBCL）』患者向けの治療薬として、ヨーロッパで初めて利用可能となるCD20xCD3 T細胞エンゲージメント型二重特異性抗体。

Glofitamab Monotherapy in Heavily Pretreated MCL #lymsm

Glofitamab Plus R-CHOP Induces High Response Rates with a Manageable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A 12-Month Analysis from a Phase Ib Study
#BiTe #Immunotherapy #ASH23
ash.confex.com/ash/2023/webpr…

Glofitamab Monotherapy in R/R LBCL: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume ash.confex.com/ash/2023/webpr… #ASH23

Look out for this at #ASCO24
Important update for #glofitamab in R/R #MCL

UK real world data Glofitamab
Kush Ediri

n=74, 17 centres 2023-2024
🔹Short fu (median 4m) but outcomes⬇️ cf trial data
🔹Median 3 prior lines, 65% 4th line
🔹CRS 32%
🔸CMR 25% ORR 46%
🔹Real world: PS diverse, histology incl, higher risk genomic profile

BSH - Haematology #BSH24

Glofitamab Monotherapy phase II

#WillTownsend

n=154
Fixed duration, all pts admitted 1st dose

☢️Total metabolic tumor volume baseline predicts PFS and ~ risk CRS

❓Useful for future risk stratification & decide drug delivery

BSH - Haematology #BSH24

Extended follow-up on glofitamab in R/R LBCL presented by Martin Hutchings #ASH23
- 1/3 pts received previous CAR-T
- TMVT linked to EFS
- Sustained response for CR-achieving patients
- CR at C3 appears to predict outcome; perhaps a pivotal point to consider a change in therapy?

Predictive model for the risk of cytokine release syndrome with glofitamab treatment for diffuse large B-cell lymphoma
ashpublications.org/bloodadvances/…
Krishna Komanduri, MD, FASTCT Blood Advances

Majority of pts with R/R DLBCL with CR at EOT are event free 18 m after
EOT with glofitamab. Fixed duration tx means better qol for our patients, less infectious risks and less costs. #ASH23 #lymsm Martin Hutchings

#ASH23
Abstract 433 - Martin Hutchings et al.

Fixed-duration glofitamab provides long-lasting remissions for patients with R/R LBCL.
#Bispecific

Glofitamab (Glofit) Plus R-CHOP Has a Favorable Safety Profile and Induces High Response Rates in Patients with Previously Untreated (1L) Large B-Cell Lymphoma (LBCL) Defined As High Risk By Circulating Tumor DNA (ctDNA) Dynamics ash.confex.com/ash/2023/webpr… #ASH23 #lymsm

$ADCT (NP)

Mental exercise- my stab at a possible thesis

Devil's advocate (reasons not to pull trigger):

-Still not enough evidence that the story is improving

-DLBCL= very crowded market with bispecifics (e.g. glofitamab) and CAR-T set to take the most share

-Dragging its